新型高弛豫率钆基对比剂钆匹醇在健康受试者及脑病变患者中的药代动力学、药效学特征与耐受性评估(I/IIa期研究)
这项单次递增剂量I/IIa期研究在54名健康受试者和12名脑病变患者中评估了钆匹醇的药代动力学、安全性和药效学。健康受试者中钆匹醇药代动力学呈线性,经肾脏以原形排泄,终末消除半衰期1.5至2小时;钆匹醇组与安慰剂组相关不良事件发生率相似(36.1% vs 33.3%)。患者中各剂量组均见充分对比增强,初步药效学结果提示钆匹醇是有前景的大环类对比剂,可能以较低剂量用于临床常规磁共振扫描。
要点
- 钆匹醇在健康受试者中药代动力学呈线性,经肾脏以原形排泄,终末消除半衰期1.5至2小时。
- 钆匹醇组相关不良事件发生率36.1%,安慰剂组33.3%,未报告有临床意义的实验室或心电图参数改变。
- 脑病变患者各测试剂量(0.05、0.075、0.1、0.2 mmol/kg)均见充分对比增强。
核心结论
- 钆匹醇在健康受试者和脑病变患者中药代动力学呈剂量非依赖性,安全性良好且与其他大环类钆基对比剂报告一致;患者初步药效学结果提示其是有前景的大环类对比剂,可能以较低剂量用于临床常规磁共振扫描。
研究设计与样本
- 单次递增剂量I/IIa期研究;I期双盲、随机、安慰剂对照,纳入54名健康受试者,每个剂量组(0.025、0.05、0.075、0.1、0.2、0.3 mmol/kg)6名接受钆匹醇、3名接受安慰剂(0.9%氯化钠)静脉注射;IIa期开放标签,纳入12名脑病变患者,每个剂量组(0.05、0.075、0.1、0.2 mmol/kg)3名;药代动力学采用非房室分析,药效学包括脑结构/病变可视化的定性评估及磁共振成像信噪比、对比噪声比定量测量。
诊断标准与关键数值
- 健康受试者中平均最大浓度Cmax范围为248.7至3916.4 μg/mL。
- 钆匹醇终末消除半衰期为1.5至2小时。
- 钆匹醇组相关不良事件发生率36.1%,安慰剂组33.3%。
临床应用与阅片要点
- 作者认为钆匹醇是有前景的大环类对比剂,可能以较低剂量用于临床常规磁共振扫描。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to evaluate the pharmacokinetics, safety profile, and pharmacodynamics of gadopiclenol, a new high relaxivity macrocyclic gadolinium-based contrast agent, in healthy subjects and patients with brain lesions.
MATERIALS AND METHODS: This was a single ascending dose phase I/IIa study. Phase I was double-blind, randomized, placebo-controlled and included 54 healthy subjects. In each dose group (0.025, 0.05, 0.075, 0.1, 0.2, and 0.3 mmol/kg), 6 subjects received gadopiclenol and 3 received placebo (NaCl 0.9%) in intravenous injection. Phase IIa was open-label and included 12 patients with brain lesions, 3 per dose group (0.05, 0.075, 0.1, and 0.2 mmol/kg). Concentrations were measured in plasma samples collected before administration and over a 24-hour period postadministration and in urine specimens (phase I) collected until 7 days after administration. A noncompartmental approach was used for pharmacokinetic analysis. Pharmacodynamic assessments included a qualitative evaluation of the visualization of brain structures/lesions and quantitative measurements (signal-to-noise ratio, contrast-to-noise ratio) on magnetic resonance imaging. A clinical and biological safety follow-up was performed up to 7 days after administration for phase I and up to 1 day after administration for phase IIa.
RESULTS: In healthy subjects (male, 50%; median age, 26.0 years), the pharmacokinetics of gadopiclenol is considered linear with mean maximum concentration Cmax values ranging from 248.7 to 3916.4 μg/mL. Gadopiclenol was excreted in an unchanged form via the kidneys, eliminated from plasma with a terminal elimination half-life (t1/2) of 1.5 to 2 hours. There was no difference in the pharmacokinetics between males and females. After administration of gadopiclenol, the contrast enhancement scores in brain structures were improved in all dose groups. Similar rates of related adverse events were observed with gadopiclenol (36.1%) and placebo (33.3%). No clinically significant modifications in biochemistry, hematology, urinalysis, electrocardiogram parameters, and vital signs were reported.In patients (male, 58%; median age, 53.0 years), a similar pharmacokinetic and safety profile was observed, and sufficient contrast enhancement was seen at all tested doses.
CONCLUSIONS: The pharmacokinetics of gadopiclenol is dose-independent in healthy subjects and patients with brain lesions. Its good safety profile is in line with that reported for other macrocyclic gadolinium-based contrast agents. Preliminary pharmacodynamic results in patients suggest that gadopiclenol is a promising macrocyclic contrast agent with the potential use of lower dose for clinical routine magnetic resonance imaging scans.The study is registered on ClinicalTrials.gov under the trial registration number NCT03603106.
引用
- Hao J, Bourrinet P, Desché P, et al. Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study). Invest Radiol. 2019. PMID: 30870257. doi:10.1097/RLI.0000000000000556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。